First-on-Target Antibody Drug Conjugate for Treatment of Advanced Colorectal Cancer
Preclinical Platform Advancing Towards IND
Novel mechanism of action - First-on-target ADC targeting with effective internalisation and payload delivery, developed over 6 years.
Lead indication - Advanced CRC - target expression rises with disease progression.
Pre-clinical efficacy - ADC shows effective cytotoxicity using off-patent payloads in human cancer cell models.
Additional indications - initial datasets on Ovarian (xenograft, syngeneic/orthotopic), Prostate (xenograft) and Triple Negative Breast cancer.
Safety evaluation - Mouse toxicology complete, clean profile.
Regulatory Advice - Medicines Discovery Catapult programme commissioned; IND-enabling roadmap delivered in collaboration with Boyds and Apconix.
Why It Matters
-
Broad Patient Coverage
Target is highly expressed in advanced colorectal cancer
-
Low Off-Tumour Effects
Minimal expression in healthy tissue, improving tolerability.
-
ADC Suitable Biology
Confirmed internalisation enables efficient payload delivery.
Our MissionOur mission is to address significant unmet need in oncology, developing targeted therapies for patients where little to no effective treatment options exist — starting with Advanced Colorectal Cancer.
Building the Next Generation of ADCs
Our focus is to complete IND-enabling studies and prepare for first-in-human evaluation of our lead ADC.
We’re seeking strategic investment and partnerships to accelerate this next stage of development — advancing a highly selective, first-on-target ADC with the potential to transform treatment for solid tumours.
Contact us.
We welcome enquiries from investors, partners, and collaborators interested in our first-on-target ADC programme.
Share a few details below, and our team will get back to you shortly.